PriceTargets.com logo

Omeros - OMER Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $40.33
  • Forecasted Upside: 315.68%
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 2 Strong Buy Ratings
$9.70 As of 06/17/2026 01:31 PM ET
▲ +0.223 (2.35%)

This chart shows the closing price for OMER by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Omeros Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OMER and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OMER

Analyst Price Target is $40.33
▲ +315.68% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Omeros in the last 3 months. The average price target is $40.33, with a high forecast of $45.00 and a low forecast of $36.00. The average price target represents a 315.68% upside from the last price of $9.70.

This chart shows the closing price for OMER for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 6 investment analysts is to moderate buy stock in Omeros. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2025
  • 1 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/22/2025
  • 1 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/20/2025
  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/19/2025
  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/19/2026
  • 2 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/18/2026
  • 2 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
6/17/2026

Latest Recommendations

  • 2 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/10/2026HC WainwrightReiterated RatingBuy ➝ Buy$40.00
6/2/2026Weiss RatingsDowngradeHold (C-) ➝ Sell (D+)
5/14/2026Weiss RatingsUpgradeSell (D-) ➝ Hold (C-)
5/14/2026HC WainwrightReiterated RatingBuy ➝ Buy$40.00
4/21/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
4/21/2026D. Boral CapitalReiterated RatingBuy ➝ Buy$36.00
4/2/2026Zacks ResearchUpgradeHold ➝ Strong-Buy
1/27/2026D. Boral CapitalReiterated RatingBuy ➝ Buy$36.00
1/22/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
1/8/2026D. Boral CapitalReiterated RatingBuy ➝ Buy$36.00
1/8/2026HC WainwrightBoost TargetBuy ➝ Buy$20.00 ➝ $40.00
12/24/2025HC WainwrightReiterated RatingBuy ➝ Buy
12/24/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$36.00
12/1/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$36.00
11/14/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$36.00
10/15/2025Needham & Company LLCReiterated RatingHold ➝ Hold
10/15/2025HC WainwrightBoost TargetBuy ➝ Buy$9.00 ➝ $20.00
10/15/2025WBB SecuritiesReiterated RatingStrong-Buy ➝ Strong-Buy$45.00
10/15/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$36.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/3/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$36.00
8/15/2025Needham & Company LLCReiterated RatingHold ➝ Hold
8/15/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$36.00
7/25/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$36.00
6/30/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$36.00
6/27/2025HC WainwrightReiterated RatingBuy ➝ Buy$9.00
6/10/2025HC WainwrightInitiated CoverageBuy$9.00
5/16/2025Needham & Company LLCReiterated RatingHold ➝ Hold
5/13/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
5/7/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
4/11/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
4/1/2025Needham & Company LLCReiterated RatingHold ➝ Hold
4/1/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
3/21/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
2/20/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
1/17/2025Needham & Company LLCReiterated RatingHold ➝ Hold
1/16/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
12/23/2024D. Boral CapitalInitiated CoverageBuy$36.00
12/19/2024Needham & Company LLCReiterated RatingHold ➝ Hold
11/14/2024Rodman & RenshawUpgradeStrong-Buy
11/14/2024Cantor FitzgeraldReiterated RatingNeutral
11/14/2024Needham & Company LLCReiterated RatingHold
11/14/2024Rodman & RenshawInitiated CoverageBuy$9.00
6/4/2024Needham & Company LLCReiterated RatingHold
5/16/2024Needham & Company LLCReiterated RatingHold
11/10/2023Cantor FitzgeraldDowngradeOverweight ➝ Neutral
7/10/2023Cantor FitzgeraldReiterated RatingOverweight
12/8/2022UBS GroupDowngradeBuy ➝ Neutral
11/10/2022Cantor FitzgeraldLower Target$20.00 ➝ $13.00
11/8/2022Bank of AmericaDowngradeNeutral ➝ Underperform$8.00 ➝ $3.00
6/8/2022Bank of AmericaDowngradeBuy ➝ Neutral$12.00 ➝ $4.00
1/18/2022Cantor FitzgeraldLower Target$34.00 ➝ $20.00
10/19/2021HC WainwrightLower TargetBuy$19.00 ➝ $12.00
10/8/2021JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
10/6/2021HC WainwrightReiterated RatingBuy$32.00 ➝ $19.00
10/1/2021WedbushDowngradeNeutral ➝ Underperform$5.00
10/1/2021Maxim GroupDowngradeBuy ➝ Hold
9/27/2021JPMorgan Chase & Co.Initiated CoverageNeutral$15.00
9/7/2021HC WainwrightReiterated RatingBuy$32.00
6/18/2021WBB SecuritiesBoost TargetStrong-Buy$75.00 ➝ $100.00
(Data available from 6/17/2021 forward)

News Sentiment Rating

0.23 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/19/2025
  • 3 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/19/2025
  • 9 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/18/2026
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/17/2026
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2026
  • 2 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/18/2026
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/18/2026
  • 2 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/17/2026

Current Sentiment

  • 2 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Omeros logo
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $9.70
Low: $9.26
High: $9.93

50 Day Range

MA: $12.12
Low: $8.73
High: $14.83

52 Week Range

Now: $9.70
Low: $2.95
High: $17.65

Volume

540,707 shs

Average Volume

1,546,239 shs

Market Capitalization

$702.25 million

P/E Ratio

13.92

Dividend Yield

N/A

Beta

2.52

Frequently Asked Questions

What sell-side analysts currently cover shares of Omeros?

The following sell-side analysts have issued reports on Omeros in the last twelve months: D. Boral Capital, HC Wainwright, Needham & Company LLC, Wall Street Zen, WBB Securities, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for OMER.

What is the current price target for Omeros?

0 Wall Street analysts have set twelve-month price targets for Omeros in the last year. Their average twelve-month price target is $40.33, suggesting a possible upside of 325.5%. WBB Securities has the highest price target set, predicting OMER will reach $45.00 in the next twelve months. D. Boral Capital has the lowest price target set, forecasting a price of $36.00 for Omeros in the next year.
View the latest price targets for OMER.

What is the current consensus analyst rating for Omeros?

Omeros currently has 1 sell rating, 1 hold rating, 2 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for OMER.

What other companies compete with Omeros?

Other companies that are similar to Omeros include Nektar Therapeutics, Perrigo, Pacira BioSciences, Assembly Biosciences and Cumberland Pharmaceuticals. Learn More about companies similar to Omeros.

How do I contact Omeros' investor relations team?

Omeros' physical mailing address is 201 ELLIOT AVENUE WEST, SEATTLE WA, 98119. The biopharmaceutical company's listed phone number is (206) 676-5000 and its investor relations email address is [email protected]. The official website for Omeros is www.omeros.com. Learn More about contacing Omeros investor relations.